Ph.D., President, Chief Executive Officer and Chairman, Metabolon, Inc.
Dr. John Ryals co-founded Metabolon, Inc. in 2002 and serves as president and CEO. Metabolon is a pioneer and leader in the field of metabolomics and its use in precision medicine and human health. Prior to Metabolon, he was a co-founder, CEO and president of Paradigm Genetics, Inc., a publicly traded agricultural biotechnology company focused on industrializing the process of gene function discovery. Dr. Ryals has 30 years’ experience in the biotechnology industry, including senior research positions at Novartis and Ciba-Geigy. He currently serves on the board of directors at AgBiome, a provider of early-stage R&D for agriculture, and the advisory board of the College of Agriculture and Life Sciences at North Carolina State University. He earned a B.A. in biology and chemistry from the University of North Texas and M.S. and Ph.D. degrees in molecular biology from the University of Texas at Dallas.
Session: The Role of Metabolomics in Precision Medicine
Major health factors, including diet, lifestyle, environment and genes, exert their influence on the body by subtly changing the metabolic composition. Metabolomics provides a snapshot of the current state of health and provides new information to help with immediate clinical decision-making. Advances in the field have made metabolomics a valuable first-line tool for assessing health. It can be used to identify perturbations of metabolic pathways associated with many diseases and quickly screen patients for health or disease status. In this session, we discuss the technology used in metabolomics and hear from health innovation leaders about how the routine use of this technology is guiding precision medicine today and the role of metabolomics in the future.